Literature DB >> 16499289

SCV-07 (SciClone Pharmaceuticals/Verta).

Richard J Aspinall1, Paul J Pockros.   

Abstract

SciClone Pharmaceuticals and Verta are developing SCV-07, the lead in a series of immnunostimulants from Verta, for the potential treatment of tuberculosis and hepatitis C virus infection. Phase II clinical trials of the compound are ongoing.

Entities:  

Mesh：

Substances：

Year:  2006        PMID： 16499289

Source DB:  PubMed          Journal:  Curr Opin Investig Drugs        ISSN： 1472-4472


  3 in total

1.  Trans-ethnic meta-analysis identifies common and rare variants associated with hepatocyte growth factor levels in the Multi-Ethnic Study of Atherosclerosis (MESA).

Authors:  Nicholas B Larson; Cecilia Berardi; Paul A Decker; Christina L Wassel; Phillip S Kirsch; James S Pankow; Michele M Sale; Mariza de Andrade; Hugues Sicotte; Weihong Tang; Naomi Q Hanson; Michael Y Tsai; Kent D Taylor; Suzette J Bielinski
Journal:  Ann Hum Genet       Date:  2015-05-22       Impact factor: 1.670

2.  Peptide-Based Antiviral Drugs.

Authors:  N Arul Murugan; K Muruga Poopathi Raja; N T Saraswathi
Journal:  Adv Exp Med Biol       Date:  2021       Impact factor: 2.622

Review 3.  A review on recent developments of indole-containing antiviral agents.

Authors:  Ming-Zhi Zhang; Qiong Chen; Guang-Fu Yang
Journal:  Eur J Med Chem       Date:  2014-10-23       Impact factor: 6.514
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.